Repro Med Systems (KRMD)
What the price implies
A reverse DCF: instead of guessing a fair value, it asks what growth today's price already assumes. How it works.
Fundamental grade
Five factors scored 1 to 9 from KRMD's latest numbers, weighted into one grade. It describes the business, not whether the stock is a buy.
Key numbers
Results from SEC filings
Fiscal years, from Repro Med Systems's 10-K filings. Ten years of the full income statement, balance sheet and cash flow.
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $23M | $28M | $29M | $34M | $41M |
| Net income | -$5M | -$9M | -$14M | -$6M | -$3M |
| Free cash flow | -$5M | -$8M | -$6M | -$2M | -$470,112 |
| EPS (diluted) | -$0.10 | -$0.19 | -$0.30 | -$0.13 | -$0.06 |
| Operating margin | -29.9% | -38.6% | -36.0% | -19.2% | -7.2% |
Where the revenue comes from
Revenue by regions, fiscal 2025. Every breakdown, year by year.
Superinvestors who own KRMD
From each investor's latest 13F filing (what a 13F shows).
Insider buying
Open-market purchases by Repro Med Systems's executives and directors in the last 12 months, from SEC Form 4 filings. What insider buying tells you.
| Date | Insider | Shares | Price | Value |
|---|---|---|---|---|
| Sep 8, 2026 | Adam R Kalbermatten Chief Commercial Officer |
32,000 | $3.16 | $101,120 |
Get an alert at your buy price
Pick the price you'd be interested at. We'll email you when KRMD trades at or below it.
New accounts get 7 days of Pro, price alerts included. No card needed.
In the full deep dive
Questions
Are Repro Med Systems insiders buying the stock?
1 open-market insider purchase of KRMD in the last 12 months, from SEC Form 4 filings.
Prices and ratios as of Oct 11, 2026; statements from SEC filings. Information only, not investment advice. Superinvestor holdings come from 13F filings, which are filed up to 45 days after each quarter ends.